Type 2 diabetes mellitus (T2DM) and cardiovascular disease are closely interconnected. We sought to determine the cardioprotective action of finerenone according to prior treatment with newer antidiabetics and glycemic status. We searched PubMed and Cochrane Library from inception to October 1, 2021 for randomized controlled trials (RCTs) assessing the effect of finerenone on major adverse cardiovascular outcomes in patients with T2DM. We set the primary endpoint as major adverse cardiovascular events (MACE), defined as the composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. We finally included two RCTs in our quantitative synthesis. Compared to placebo, finerenone induced a 23% risk reduction for the composite cardiovascular endpoint, regardless of prior glycemia. We also showed that finerenone provided significant cardiovascular benefit for obese patients with T2DM compared to placebo, although this benefit was diminished for subjects with a body mass index lower than 30 kg/m2. Finally, the combination of finerenone with sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists did not produce a significant risk reduction for MACE. We conclude that finerenone provides significant cardiovascular benefits for patients with T2DM, especially for those who are obese, while glycemic status or treatment with newer antidiabetics at baseline does not affect the observed cardioprotective action.
Citations
Citations to this article as recorded by
Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors M. Sanz-Gómez, F.J. Manzano-Lista, E. Vega-Martín, D. González-Moreno, M. Alcalá, M. Gil-Ortega, B. Somoza, C. Pizzamiglio, L.M. Ruilope, I. Aránguez, P. Kolkhof, R. Kreutz, M.S. Fernández-Alfonso Biomedicine & Pharmacotherapy.2023; 168: 115661. CrossRef
Research Progress in Finerenone in Cardiovascular Diseases Sun Xue, Dong Yanghong, Gu Jiaxin, Liu Wenxiu, Liu Yue Cardiovascular Innovations and Applications.2023;[Epub] CrossRef
The coronavirus disease 2019 (COVID-19) pandemic remains an unbeaten enemy. Unfortunately, no targeted treatment option is available. Patients with type 2 diabetes mellitus (T2DM) have increased odds for severe or fatal disease, as demonstrated in recent observational studies. There is an ongoing discussion regarding the impact of different antidiabetic drug classes on outcomes of interest among affected subjects. Dipeptidyl peptidase-4 (DPP-4) inhibitors have been placed at the epicenter, since the DPP-4 enzyme seems to be implicated in the disease pathogenesis. Herein we present an updated meta-analysis of observational studies addressing the risk of COVID-19 death among patients with T2DM on prior DPP-4 inhibitor treatment. We pooled data from 10 observational studies, showing that DPP-4 inhibitors produce a non-significant decrease in the risk for COVID-19-related death. However, when administered in the inpatient setting, DPP-4 inhibitors decrease the risk for COVID-19-related death by 50%. Ongoing randomized controlled trials will shed further light.
Citations
Citations to this article as recorded by
Noninsulin‐based antihyperglycemic medications in patients with diabetes and COVID‐19: A systematic review and meta‐analysis Mahmoud Nassar, Hazem Abosheaishaa, Awadhesh Kumar Singh, Anoop Misra, Zachary Bloomgarden Journal of Diabetes.2023; 15(2): 86. CrossRef
Effects of novel glucose-lowering drugs on the COVID-19 patients with diabetes: A network meta-analysis of clinical outcomes Yang Yang, Ling Zhao, Yeying Wang, Chengjiang Liu, Tingyu Ke International Journal of Diabetes in Developing Countries.2023;[Epub] CrossRef
COVID-19 and metabolic syndrome Harsha Dissanayake Best Practice & Research Clinical Endocrinology & Metabolism.2023; 37(4): 101753. CrossRef
Current management of diabetes patients with COVID-19 Arup Kumar Misra, Gaurav Rangari, Madhavrao C, Sushil Sharma Expert Review of Endocrinology & Metabolism.2023; 18(2): 199. CrossRef
Current management of diabetes patients with COVID-19 Arup Kumar Misra, Gaurav Rangari, Madhavrao C, Sushil Sharma Expert Review of Endocrinology & Metabolism.2023; : 1. CrossRef
Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes Andreana Foresta, Luisa Ojeda-Fernandez, Giulia Macaluso, Maria Carla Roncaglioni, Mauro Tettamanti, Ida Fortino, Olivia Leoni, Stefano Genovese, Marta Baviera Clinical Therapeutics.2023; 45(4): e115. CrossRef
DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes Snehasish Nag, Samanwita Mandal, Oindrila Mukherjee, Suprabhat Mukherjee, Rakesh Kundu Future Virology.2023; 18(5): 321. CrossRef
DrugRep-HeSiaGraph: when heterogenous siamese neural network meets knowledge graphs for drug repurposing Zahra Ghorbanali, Fatemeh Zare-Mirakabad, Najmeh Salehi, Mohammad Akbari, Ali Masoudi-Nejad BMC Bioinformatics.2023;[Epub] CrossRef
Immunomodulatory activity of dipeptidyl peptidase‐4 inhibitors in immune‐related diseases Marija Drakul, Miodrag Čolić European Journal of Immunology.2023;[Epub] CrossRef
Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis Ahmad Fariz Malvi Zamzam Zein, Wilson Matthew Raffaello Primary Care Diabetes.2022; 16(1): 162. CrossRef
Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis Nam Nhat Nguyen, Dung Si Ho, Hung Song Nguyen, Dang Khanh Ngan Ho, Hung-Yuan Li, Chia-Yuan Lin, Hsiao-Yean Chiu, Yang-Ching Chen Metabolism.2022; 131: 155196. CrossRef
The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis Yidan Chen, Xingfei Lv, Sang Lin, Mohammad Arshad, Mengjun Dai Frontiers in Endocrinology.2022;[Epub] CrossRef
Type 2 Diabetes Mellitus and COVID-19: A Narrative Review Cristina Rey-Reñones, Sara Martinez-Torres, Francisco M. Martín-Luján, Carles Pericas, Ana Redondo, Carles Vilaplana-Carnerero, Angela Dominguez, María Grau Biomedicines.2022; 10(9): 2089. CrossRef
Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology Alba Sebastián-Martín, Belén G. Sánchez, José M. Mora-Rodríguez, Alicia Bort, Inés Díaz-Laviada Biomedicines.2022; 10(8): 2026. CrossRef
Non-Insulin Novel Antidiabetic Drugs Mechanisms in the Pathogenesis of COVID-19 Teodor Salmen, Valeria-Anca Pietroșel, Bianca-Margareta Mihai, Ioana Cristina Bica, Claudiu Teodorescu, Horia Păunescu, Oana Andreia Coman, Doina-Andrada Mihai, Anca Pantea Stoian Biomedicines.2022; 10(10): 2624. CrossRef
Antidiabetic treatment and COVID-19 Outcomes: A population-based cohort study in primary health care in Catalonia during the first wave of the pandemic Dan Ouchi, Carles Vilaplana-Carnerero, Vanessa de Dios, Maria Giner-Soriano, Rosa Morros Primary Care Diabetes.2022; 16(6): 753. CrossRef
Immunotropic effects of hypoglycemic agents on coronavirus infection: a view from the perspective of pharmacogenetics Konstantin G. Gurevich, Yulia A. Sorokina, Alexander L. Urakov, Snezhana D. Sinyushkina, Maria I. Pryazhnikova, Alyona V. Gorinova, Lyubov V. Lovtsova, Olga V. Zanozina Reviews on Clinical Pharmacology and Drug Therapy.2022; 20(3): 269. CrossRef
Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control Niya Narayanan, Dukhabandhu Naik, Jayaprakash Sahoo, Sadishkumar Kamalanathan World Journal of Virology.2022; 11(6): 399. CrossRef
Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression Maria Ida Maiorino, Miriam Longo, Lorenzo Scappaticcio, Giuseppe Bellastella, Paolo Chiodini, Katherine Esposito, Dario Giugliano Cardiovascular Diabetology.2021;[Epub] CrossRef